Abstract
Whole-breast external beam radiotherapy (WB-EBRT) is the standard of care in the UK among patients with early invasive breast cancer (BC) following breast-conserving surgery but is associated with short- and long-term adverse effects. The INTRABEAM® device may be used to deliver adjuvant targeted intraoperative radiation therapy (TARGIT-IORT) to patients with early BC at the time of surgery, while reducing treatment-associated burden, resource utilization, and exposure to radiation and relevant toxicities. An economic evaluation was performed to assess the cost-effectiveness of INTRABEAM over a lifetime horizon, from a UK National Health Service (NHS) perspective.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
